Reverse mergers have once again lost their luster. An alternative to going public, reverse mergers once carried a negative stigma. But the financing vehicle gained newfound attention in recent years as the biotech IPO market soured and private companies lined up to take the place of down-and-out publicly-traded drug developers. At least 16 such deals were announced in 2024, according to a tally from William Blair bankers. Fewer than five reverse mergers have been disclosed so far in 2025, including the planned combinations of Salarius Pharmaceuticals with Decoy Therapeutics and Eyenovia with Betaliq.
Read the full article: At a Crossroads, Biotechs Are Passing on Reverse Mergers in 2025 //
Source: https://endpoints.news/at-a-crossroads-biotechs-are-passing-on-reverse-mergers-in-2025/